Ito T

Janssen EMEA, High Wycombe ,

5 papers

ArticleKetamine

Improvements in Functioning with Esketamine Nasal Spray versus Quetiapine Extended Release in Patients with Treatment Resistant Depression

Vieta E, Ahmed N, Arango C +11

Europe PMC2025
ArticleKetamine

Outcomes with esketamine nasal spray in patients with or without earlier partial or full response: post hoc analyses of ESCAPE TRD

Young A, Godinov Y, Rive B +8

Europe PMC2025
ArticleKetamine

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.

Vieta E, Ahmed N, Arango C +11

Europe PMC2025
ArticleKetamine

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

McIntyre RS, Bitter I, Buyze J +9

Europe PMC2024
ArticleKetamine

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

Reif A, Anıl Yağcıoğlu A, Luts A +10

Europe PMC2023